A commercial process to manufacture sotorasib (AMG 510),
a first-in-class
KRASG12C inhibitor, is described. Development efforts focused
on rendering a fit-for-purpose early-phase route into a viable long-term
commercial process through the reduction of side reactions to improve
yield and product quality, as well as reducing cycle times of crystallization
processes by improving particle properties and filtration times. These
improvements were key to ensuring clinical supply and commercial launch.
The final route consists of five synthetic operations from starting
material
M-1, including a telescoped
two-step sequence, and a final form-setting crystallization.